Albers P

Bodrogi I

Cleall SP

Conte PF

Dogliotti L

Hansen SW

Kerbrat P

Knuth A

Lippert CM

Moore MJ

Oliver T

Roberts JT

Rovira PS

Roychowdhury DF

Tomlin I

Visseren-Grul CM

von der Maase H

Wersall P

Purpose: Gemcitabine plus cisplatin (OC) and methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) were compared in patients with locally advanced or metastatic transitional-cell carcinoma (TCC) of the urothelium. Patients and Methods: Patients with stage IV TCC and no prior systemic chemotherapy were randomized to OC (gemcitabine 1,000 mg/m(2) days 1, 8, and 15; cisplatin 70 mg/m(2) day 2) or standard MVAC every 28 days for a maximum of six cycles. Results: Four hundred five patients were randomized (GC, n = 203; MVAC, n = 202). The groups were well-balanced with respect to prognostic factors. Overall survival was similar on both arms (hazards ratio [HR], 1.04; 95% confidence interval [CI], 0.82 to 1.32; P =.75), as were time to progressive disease (HR, 1.05; 95% CI, 0.85 to 1.30), time to treatment failure (HR, 0.89: 95% CI, 0.72 to 1.10), and response rate (GC, 49%; MVAC, 46%). More OC patients completed six cycles of therapy, with fewer dose adjustments. The toxic death rate was 1% on the GC arm and 3% on the MVAC arm. More GC than MVAC patients had grade 3/4 anemia (27% v 18%, respectively) and thrombocytopenia (57% v 21%, respectively). On both arms, the RBC transfusion rate was 13 Of 100 cycles and grade 3/4 hemorrhage or hematuria was 2%; the platelet transfusion rate war four patients per 100 cycles and two patients per 100 cycles on GC and MVAC, respectively. More MVAC patients, compared with GC patients, had grade 3/4 neutropenia (82% v 71%, respectively), neutropenic fever (14% v 2%, respectively), neutropenic sepsis (12% v 1%, respectively), and grade 3/4 mucositis (22% v 1%, respectively) and alapecia (55% v 11%, respectively). Quality of life was maintained during treatment on both arms; however, more patients on GC fared better regarding weight, performance status, and fatigue. Conclusion: GC provides a similar survival advantage to MVAC with a better safety profile and tolerability. This better-risk benefit ratio should change the standard of care for patients with locally advanced and metastatic TCC from MVAC to OC. (C) 2000 by American Society of Clinical Oncology

Newcastle University E-Prints

Gemcitabine and cisplatin versus methotrexate vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study

Gemcitabine and cisplatin versus methotrexate vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study

Abstract

Similar works

Full text

Available Versions

Newcastle University E-Prints